Healius (ASX:HLS) Announces Pathology Strategy and $300M Dividend at Investor Day 2025
Healius (ASX:HLS) reveals a new pathology strategy and a $300 million special dividend during Investor Day 2025.
Category: ASX-HLS
Healius
Latest News
Clarity Pharmaceuticals (ASX:CU6) Signs Copper-64 Supply Agreement with Nusano
Anatara Lifesciences (ASX:ANR) Announces Phase II GaRP-IBS Trial Results
Dreadnought Resources Ltd (ASX:DRE) Completes Share Purchase Plan
West African Resources Limited (ASX:WAF) Publishes Quarterly Cash Flow Report
Podium Minerals (ASX:POD) Completes EV Nickel Acquisition and Joins WPIC
Imricor Medical Systems (ASX:IMR) Receives CE Mark Approval for Advantage-MR System
Tourism Holdings Limited (ASX:THL) Releases FY25 Trading Update
Streamplay Studio Limited (ASX:SP8) Announces Global Launch of Sacre Bleu on Nintendo Switch & Steam
CZR Resources Ltd (ASX:CZR) Announces Trading Halt
Pilbara Minerals (ASX:PLS) Reports March Quarter Production and Financial Metrics
The Hub of Australian Finance News